An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer
- 1 August 2003
- Vol. 62 (2) , 319-323
- https://doi.org/10.1016/s0090-4295(03)00330-3
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerClinical Therapeutics, 2002
- A Clinical Study Of 22.5 mg. La-2550: A New Subcutaneous Depot Delivery System For Leuprolide Acetate For The Treatment Of Prostate CancerJournal of Urology, 2002
- SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCERJournal of Urology, 2000
- FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHMJournal of Urology, 2000
- Inhibition of Gonadotropin-Releasing Hormone Receptor Signaling by Expression of a Splice Variant of the Human ReceptorMolecular Endocrinology, 1997
- Functional consequences of the phosphorylation of the gonadotropin receptorsBiochemical Pharmacology, 1996
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- Diversity and Selectivity of Receptor-G Protein InteractionAnnual Review of Pharmacology and Toxicology, 1996
- Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptorBiochemical Journal, 1994
- Flushing long-term side effect of orchiectomy in treatment of prostatic carcinomaUrology, 1989